TABLE 2.
Biofilm inhibitory activities of the synthesized compounds.
| Entry | Compound | MBIC (µg/mL) | Entry | Compound | MBIC (µg/mL) | Entry | Compound | MBIC (µg/mL) |
|---|---|---|---|---|---|---|---|---|
| 1 | 8aA | 80 | 11 | 8bI | 80 | 21 | 8fE | >100 |
| 2 | 8aC | 80 | 12 | 8cC | 34.26 ± 1.74 | 22 | 8gE | >100 |
| 3 | 8aD | 80 | 13 | 8cD | 80 | 23 | 8hA | 80 |
| 4 | 8aJ | 80 | 14 | 8cE | 14.31 ± 2.44 | 24 | 8iA | 80 |
| 5 | 8bA | 80 | 15 | 8cF | 42.16 ± 1.86 | 25 | 8iB | 80 |
| 6 | 8bB | 80 | 16 | 8cI | 80 | 26 | 8iD | 80 |
| 7 | 8bC | 50–55 | 17 | 8dG | 36.49 ± 1.87 | 27 | 8jB | >100 |
| 8 | 8bD | 50–55 | 18 | 8dH | 24.32 ± 2.54 | 28 | 8kG | >100 |
| 9 | 8bE | 10.42 ± 2.18 | 19 | 8eC | 45 ± 1.07 | 29 (Al-Musawi et al., 2020) | Trans-chalcone | 20 |
| 10 | 8bF | 45.36 ± 3.24 | 20 | 8eD | 80 | 30 (Park et al., 2022) | Kanamycin | 50 |
The bold value highlights the highest MBIC values obtained by prepared derivatives.